Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Pulmonary Tuberculosis IV

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Tuberculosis

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges.

International journal of pharmaceutics: X·2026

Same author

Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trials.

The Lancet. Microbe·2025

Same author

Model-Informed Drug Development of a Sustained Release Formulation of Flucytosine in the Treatment of Cryptococcal Meningitis: A Case Study Using Physiologically Based Pharmacokinetic Modeling.

CPT: pharmacometrics & systems pharmacology·2025

Same author

Improving access to liposomal amphotericin B worldwide - Authors' reply.

The Lancet. Global health·2024

Same author

Bioavailability of a novel sustained-release pellet formulation of 5-flucytosine in healthy-fed participants for use in patients with cryptococcal meningitis.

Clinical and translational science·2024

Same author

Paving the way for affordable and equitable liposomal amphotericin B access worldwide.

The Lancet. Global health·2024

Search research articles

Related Experiment Video

Updated: Jul 12, 2026

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

Published on: October 25, 2024

Treatment Options for HIV-Associated Tuberculosis.

Philip Chukwuka Onyebujoh¹, Isabela Ribeiro, Christopher Curtis Whalen

¹United Nations Children's Fund/United Nations Development Programme/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland. onyebujohp@who.int

The Journal of Infectious Diseases

|August 31, 2007

Summary

Managing tuberculosis (TB) in patients with human immunodeficiency virus (HIV) infection presents unique challenges. This review covers current strategies, novel approaches, and research needs for effective HIV-associated TB care.

Related Experiment Videos

Last Updated: Jul 12, 2026

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

Published on: October 25, 2024

Area of Science:

Infectious Diseases
Public Health
Clinical Medicine

Background:

The co-occurrence of human immunodeficiency virus (HIV) and tuberculosis (TB) pandemics creates significant challenges for global health.
Managing TB in HIV-infected individuals is complex due to various clinical and systemic factors.

Purpose of the Study:

To review current and novel treatment strategies for HIV-associated TB.
To identify gaps in knowledge and propose a research agenda for managing this dual infection.

Main Methods:

Literature review of recommended treatment strategies for TB in HIV-infected patients.
Analysis of challenges including diagnostics, adherence, drug interactions, and paradoxical reactions.
Exploration of adjuvant treatments and treatment simplification options.

Main Results:

Treatment recommendations for TB in HIV-infected patients are similar to those for HIV-uninfected patients but complicated by practical issues.
Adjuvant therapies and simplified treatment regimens are being explored.
Significant knowledge gaps remain, necessitating further research.

Conclusions:

Effective management of HIV-associated TB requires addressing health system weaknesses and clinical complexities.
Novel approaches and targeted research are crucial for improving patient outcomes and control programs.